16.03.2023 • NewsNovo NordiskInsulindrugmaker

Novo Nordisk to Cut US Insulin prices from 2024

Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price cuts and in response to growing pressure from the White House.

In his State-of-the-Union address earlier this year, President Joe Biden repeated his calls for a cap of $35.

On Mar.14, Novo Nordik said it would lower the list price of its NovoLog insulin by 75% and drop the price of Novolin and Levemir by 65% with effect from the beginning of 2024.

In a statement, the drugmaker said, “we have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes.”

Specifically, the cost of a five-pack of NovoLog injection pens should fall from $558.83 to $139.71, while a vial would cost $72.34 instead of $289.36. A single Levemir injection pen would carry a price tag of $161.77, and a vial would cost $107.85

© Shutterstock/ ittipon
© Shutterstock/ ittipon

Lilly said earlier this month that it planned to cut prices of its most commonly prescribed diabetes treatments by 70% and also cap the co-pay for insured patients at $35 per month. For the most part, the prices quoted are still higher than those paid by patients with health insurance coverage, reports say.

In an announcement last year, as the US political discussion about insulin prices reached a new peak, Sanofi suggested it would reduce prices for its Lantus-brand insulin for uninsured people in the US by two-thirds, from $99 per month to $35.

Together, the three drugmakers are seen as controlling the US insulin market.

Author: Dede Williams, Freelance Journalist

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.